Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
Status:
Terminated
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Treatment with Burixafor hydrobromide will effectively mobilize metastatic
prostate cancer (PCa) cells (i.e. disseminated tumor cells; DTCs) into the blood from the
bone marrow. It has been demonstrated that prostate cancer cells have been mobilized out of
the bone marrow of mice utilizing an anti-CXCR4 strategy; making them more susceptible to
chemotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Prostate Cancer Foundation TaiGen Biotechnology Co., Ltd.